全球首个经鼻眼底显微手术导航系统、全国首家人工视网膜医学芯片公司、全球首款0.01%低浓度阿托 品……这一系列突破性的"第一"，全部与一个硬核园区息息相关——中国眼谷。 近日，记者跟随中国残联走基层活动，来到位于浙江温州的中国眼谷小镇。2020年6月，由温州医科大 学附属眼视光医院（以下简称"眼视光医院"）与温州市龙湾区共同建设的中国眼谷正式开园。作为全球 首个眼健康科创、产业综合体，近年来，中国眼谷以科技创新带动产业升级，以成果转化促进产业壮 大，在"小眼球"上作出产业发展"大文章"。 在眼谷之瞳的展厅内，一台高分辨率视觉脑机接口设备吸引了投资者们注目。这台设备来自暖芯迦科技 （温州）有限公司，其搭载的脑机连接人工视网膜系统融合了多学科技术，包括脑机接口、人工智能和 工程仿生学等，适用于因各种原因导致的后天性视网膜严重器质性病变而失明者。 2022年，杭州暖芯迦电子科技有限公司董事长杨佳威带领团队入驻中国眼谷。目前，暖芯迦与中国眼谷 合作项目已于2024年下半年完成医疗器械型式检验。数据显示，该技术的移植分辨率超过1000像素，成 功移植后能够有效补偿患者视觉功能，帮助失明者生活自理。 眼视光装备、视觉光学 ...

Group 1 - Jinggong Technology signed a sales contract with Hubei Yuchuang worth 729 million yuan, accounting for 42.16% of the company's audited revenue for 2024 [1] - Heshun Electric is expected to win a bid for a State Grid procurement project worth 107 million yuan, representing 24.97% of the company's 2024 revenue [2] - Yongmaotai plans to invest approximately 400 million yuan in a new intelligent manufacturing project for magnesium-aluminum alloy materials [3] Group 2 - Longi Green Energy announced the termination of its plan to issue global depositary receipts abroad, stating it will not significantly impact its operations [4] - Bai Ao Intelligent is expected to win bids for projects totaling 27.5 million yuan [5] - Lian Biological is planning a change of control and asset purchase, leading to a temporary suspension of its stock [6] Group 3 - Bo Rui Communication intends to acquire 51% of Meijing Technology for 66.49 million yuan [7] - Huitai Medical plans to repurchase shares worth 200 to 250 million yuan for employee stock ownership plans [8] - Yifang Biological is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] Group 4 - Jiuqiang Biological's shareholders signed an agreement for the transfer of 5% of the company's shares to China National Pharmaceutical Investment [11] - Songcheng Performing Arts plans to repurchase shares worth 100 to 200 million yuan for capital reduction [12] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project in Jiangxi Province [13] Group 5 - Xingfu Electronics plans to invest 480 million yuan in a new electronic-grade phosphoric acid project [14] - Jiaao Environmental Protection's stock will be subject to risk warnings due to an administrative penalty [15] - ST Nuotai received a drug registration certificate for a new injection [16] Group 6 - Haimo Technology plans to sell its controlling subsidiary, Xian Sitian Instrument, for 370 million yuan [17] - Jingce Electronics signed multiple sales contracts with a single customer totaling 433 million yuan [18] - Donghua Testing's controlling shareholder plans to reduce its stake by up to 1.99% [19][20] Group 7 - Xingqi Eye Medicine completed the first subject enrollment for a Phase II clinical trial of its eye drop product [21] - Kute Intelligent's controlling shareholder plans to reduce its stake by up to 2% [22] - Dongcheng Pharmaceutical's subsidiary received approval for a new specification of a heparin sodium injection [23] Group 8 - Zhaoyi Innovation is in the process of issuing H-shares and has received regulatory approval [24] - Aokang International's shareholder plans to reduce its stake by up to 3% [25] - Jiamei Packaging's controlling shareholder is planning a change of control, leading to a temporary stock suspension [26] Group 9 - ST Kevin's stock will have its risk warning lifted and will resume trading [27] - Zaiseng Technology's controlling shareholder plans to transfer 6.04% of the company's shares [28] - Lide New Energy's shareholder plans to reduce its stake by up to 1% [29] Group 10 - Srypu terminated its plan to acquire shares and will resume trading [30] - Longjiang Transportation's subsidiary plans to invest 2.679 billion yuan in a graphite mining project [31] - Haowei Group's controlling shareholder has not reduced its stake and has terminated the reduction plan [32] Group 11 - Huilun Crystal received an administrative penalty notice for information disclosure violations [33] - Haiguang Information terminated a major asset restructuring plan [34] - Zhongke Shuguang announced a cash dividend plan [35] Group 12 - Fushuo Technology's share purchase plan was approved by the Shenzhen Stock Exchange [36] - Dongbai Group's shareholder reduced its stake by 25.95 million shares [38]

Market Overview - US stock market showed mixed performance ahead of the Federal Reserve's decision, with the S&P 500 and Dow Jones experiencing two consecutive declines, while the Nasdaq saw a slight rebound, closing with a 0.13% increase [1] - Morgan Stanley led the decline in the Dow, dropping nearly 5%, while Nvidia fell 0.3% and Broadcom rose over 1%, reaching a historical high [1] - The Nasdaq Golden Dragon China Index fell by 1.37%, with Baidu down nearly 5% and Xpeng down over 3% [1] Economic Indicators - Unexpected improvement in US job vacancies led to a rise in the dollar index, reaching a one-week high, while US Treasury prices fell, causing a V-shaped recovery in yields, with the 10-year Treasury yield nearing a two-month high [2][3] - Bitcoin surged over 5%, surpassing $94,000, and Ethereum rose nearly 10% following the job vacancy report [3] Corporate Developments - Microsoft announced a total of $23 billion in new AI investments, including $17.5 billion in India, marking the largest investment in Asia [4] - SpaceX is reportedly seeking to go public in 2026, aiming to raise over $30 billion with a valuation of $1.5 trillion, marking a potential record IPO [3] Industry Insights - Huawei's automotive division announced a strategic partnership to enhance its electric vehicle offerings, with a significant increase in sales reported for November, achieving a record monthly delivery of 81,864 units, up 89.61% year-on-year [7] - The establishment of a multi-crystalline silicon capacity integration acquisition platform, Beijing Guanghe Qiancheng Technology Co., Ltd., with a registered capital of 3 billion yuan, aims to explore strategic cooperation opportunities within the industry [8] - The upcoming 2025 Computing Power Industry Ecosystem High-Quality Development Conference will focus on the future of the computing power industry, highlighting the growth of AI computing hardware [9] Retail Sector Trends - The retail industry in China is undergoing a transformation from scale expansion to quality enhancement, with expectations for the market size to exceed 50 trillion yuan by 2025, growing at a steady rate of 5-8% [11]

登录新浪财经APP 搜索【信披】查看更多考评等级 | | | 12月9日重要公告摘要 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | | 天源迪科 | 董事长陈友被实施留置 | | | 龙洲股份 | 不涉及商业航天相关业务 | | | 思瑞浦 | 决定终止购买奥拉股份股权 股票明起复牌 | | | 嘉美包装 | 控股股东筹划控制权变更 股票明起停牌 | | | 厦门空港 | 筹划收购兆翔科技100%股权 | | | 大业股份 | 江北公司主要从事航天动力系统、天线罩等航天产品研发生产 | | | 再升科技 | 控股股东郭茂拟协议转让6.04%公司股份给中融华信 | | 今日聚焦 | ST凯文 | 撤销其他风险警示 股票简称变更为"凯撒文化" | | | 航天发展 | 第四大股东航天科工资产公司12月9日减持134.35万股 | | | 兴福电子 | 拟投资4.8亿元建设4万吨/年电子级磷酸项目 | | | 骏亚科技 | 公司越南工厂根据投资计划处于正常建设当中 尚未投产 | | | 莱茵生物 | 控股股东筹划控制权变更 股票明日停牌 | | | 复星医药 | 控股子公司与 ...

Core Viewpoint - The company has initiated the Phase II clinical trial for its SQ-22031 eye drops, aimed at treating moderate to severe dry eye syndrome, marking a significant step in its research and development efforts [1] Group 1: Clinical Trial Details - The SQ-22031 eye drops have completed the enrollment of the first subject in a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study [1] - The primary objective of the Phase II study is to evaluate the efficacy and safety of SQ-22031 eye drops in patients with moderate to severe dry eye [1] - The study will also analyze the immunogenicity of the product and its impact on corneal nerve density changes [1]

Core Viewpoint - The company Xingqi Eye Medicine (300573) has announced the initiation of a Phase II clinical trial for its eye drop product SQ-22031, aimed at treating moderate to severe dry eye syndrome, with the first subject enrolled in the study [1] Group 1 - The clinical trial for SQ-22031 is a multicenter, randomized, double-blind, placebo-controlled study [1] - As of now, there are no approved drugs of the same category listed on the National Medical Products Administration's website [1]

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-063 沈阳兴齐眼药股份有限公司 剂型：滴眼液 适应症：干眼 临床试验批准通知书编号：2024LP01683、2024LP01684、2024LP01685、 2024LP01686 关于SQ-22031滴眼液治疗中至重度干眼Ⅱ期临床试验 首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的SQ-22031滴眼液 于今日完成了"一项评估SQ-22031滴眼液治疗中至重度干眼的有效性和安全性 的多中心、随机、双盲、安慰剂对照的Ⅱ期临床研究"首例受试者入组，正式 进入Ⅱ期临床试验。现将有关内容公告如下： 一、基本情况 药物名称：SQ-22031滴眼液 注册分类：治疗用生物制品1类 临床试验分期：Ⅱ期 二、临床试验相关情况 干眼（Dry Eye，DE）是一类多因素导致的眼表疾病，表现为泪液的质、量 及流体动力学异常引起的泪膜不稳定或眼表微环境失衡，可伴有泪液渗透压升高 以及眼表组织炎性反应、损伤、神经异常，临床出现眼部干涩、烧灼感、畏光 ...

融券方面，当日融券卖出1.26万股，融券偿还4500.0股，融券净卖出8100.0股，融券余量12.66万股，近3 个交易日已连续净卖出累计1.2万股，近20个交易日中有11个交易日出现融券净卖出。 | 交易日 | 融) 田學院論 | | 融券会量(股) | 融券余额(元) | | --- | --- | --- | --- | --- | | 2025-12-08 | | 8100.0 | 12.66万 | 925.23万 | | 2025-12-05 | | 3600.0 | 11.85万 | 864.61万 | | 2025-12-04 | | 300.0 | 11.49万 | 843.97万 | | 2025-12-03 | | -1800.0 | 11.46万 | 817.13万 | | 2025-12-02 | | 2000.0 | 11.64万 | 831.24万 | 融资融券余额11.77亿元，较昨日上涨0.26%。 证券之星消息，12月8日，兴齐眼药（300573）融资买入5013.21万元，融资偿还4765.73万元，融资净买 入247.49万元，融资余额11.68亿元，近3个交易日已连续 ...

截至2025年12月8日收盘，兴齐眼药（300573）报收于73.09元，较前一交易日上涨0.16%，最新总市值 为180.12亿元。该股当日开盘73.19元，最高74.18元，最低72.97元，成交额达4.49亿元，换手率为 3.23%。 最新公告列表 《关于公司产品继续纳入医保目录的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近日，国家医保局等部门发布《国家基本医疗保险、生育保险和工伤保险药品目录》（2025年），沈阳 兴齐眼药股份有限公司共有39个产品继续纳入国家医保药品目录，其中甲类8个，乙类31个，无产品退 出。环孢素滴眼液(Ⅱ)、复方电解质眼内冲洗液、玻璃酸钠滴眼液等继续纳入。加替沙星眼用凝胶取 消'限二线用药'限制。新版目录自2026年1月1日起执行。该事项长期对公司经营业绩有积极影响，短期 无重大影响。 ...

Group 1: National Medical Insurance Directory Inclusion - Heng Rui Medicine has multiple drugs included in the 2025 National Medical Insurance Directory [1] - Xing Qi Eye Medicine has 39 products continuing to be included in the National Medical Insurance Drug Directory [1] - Bei Da Pharmaceutical has four products included in the National Medical Insurance Drug Directory [1] - Junshi Biosciences has added indications for Tuoyi® and included Junshida® in the National Medical Insurance Directory [1] - Zhongsheng Pharmaceutical's innovative drug Angladiwei tablets have been included in the National Medical Insurance Directory through negotiation [1] - Yiling Pharmaceutical's subsidiary has its exclusive product Qifang Nasal Tablets included in the National Medical Insurance Directory, totaling 12 exclusive patented traditional Chinese medicine products [1] - Aosaikang's product Liratinib tablets (Aoyi Xin®) has been included in the 2025 National Medical Insurance Directory [1] - Kanghong Pharmaceutical's product Kangbai Xip eye injection (Langmu) has been included in the 2025 National Medical Insurance Directory [1] - Dongcheng Pharmaceutical's Technetium-99m injection has been included in the medical insurance directory; its subsidiary has received clinical trial approval for 177Lu-LNC1009 injection [1] - Micron Biomedical's Sidabena tablets have been included in the National Medical Insurance Directory for regular Class B management [1] - Haichuang Pharmaceutical's Deuteroenzalutamide soft capsules have been included in the National Medical Insurance Directory for the first time [1] - Huadong Medicine's subsidiary products and cooperative products have been included in the National Medical Insurance and commercial insurance innovative drug directory [1] - Aidi Pharmaceutical's two anti-HIV innovative drugs continue to be included in the National Medical Insurance Directory through a simplified renewal process [1] Group 2: Corporate Developments - Hengyin Technology has signed a cooperation agreement with Muxi Co., focusing on the domestic GPU scenario [1] - Jia Jian Co. is planning a change in control, with stock resuming trading on December 8 [2] - Gu Ao Technology's actual controller is planning a change in control, leading to stock suspension [2] Group 3: Financial Performance - Tianbang Food reported a commodity pig sales revenue of 654 million yuan in November, a month-on-month increase of 7.66% [3] - Tian Ci Materials' controlling shareholder has committed not to reduce company shares [3]